CAR T-cell Therapy | Specialty

The OncLive CAR T-cell therapy condition center page is a comprehensive resource for clinical news and expert insights on FDA-approved and investigational CAR T-cell products in hematologic malignancies, specifically acute lymphoblastic leukemia, non-Hodgkin lymphoma, and multiple myeloma. CAR T-cell research in solid tumors is also under exploration. This page features news articles, interviews in written and video format, and podcasts that focus on updates with CAR T-cell therapy and the ongoing research with this type of treatment.

Dr Battiwalla on the Utility of Emerging Therapies for Aggressive FL Management

November 19th 2024

Minoo Battiwalla, MD, MS, discusses how emerging therapies contribute to the management of aggressive variants of follicular lymphoma.

Early Serum IL-2 Levels Are Associated With CAR T-Cell Expansion Post–CAR T-Cell Therapy

November 11th 2024

Early cytokine induction after CAR T-cell therapy infusion predicts CAR expansion in patients with leukemia or lymphoma treated with axi-cel or brexu-cel.

The OncFive: Top Oncology Articles for the Week of 11/3

November 9th 2024

Obe-cel wins FDA approval in relapsed/refractory B-cell ALL, FDA approval is sought for sunvozertinib in EGFR exon 20–positive NSCLC, and more.

FDA Approves Obecabtagene Autoleucel for R/R B-Cell Precursor Acute Lymphoblastic Leukemia

November 8th 2024

The FDA has approved obecabtagene autoleucel for relapsed/ refractory B-cell precursor acute lymphoblastic leukemia.

Indirect Comparison Shows Superiority of Cilta-Cel vs SOC Regimens in Lenalidomide-Refractory Myeloma

November 1st 2024

Michel Delforge, MD, PhD, discusses an indirect comparison of cilta-cel vs standard-of-care regimens in lenalidomide-refractory multiple myeloma.

FDA Grants Regenerative Medicine Advanced Therapy Designation to ALLO-316 in CD70+ Advanced RCC

October 31st 2024

The FDA has granted regenerative medicine advanced therapy to ALLO-316 in CD70-positive advanced or metastatic renal cell carcinoma.

Dr Fisher on the Integration of Bispecific Antibodies and CAR T-cell Therapy into CRS Treatment

October 29th 2024

David C. Fisher, MD, discusses treatment with bispecific antibodies and CAR T-cell therapy, respectively, for patients with cytokine release syndrome.

The Future of Hematologic Cancer Care Shifts Toward Personalized and Chemotherapy-Free Regimens

October 29th 2024

Daniel DeAngelo MD, PhD, discusses the evolution of management strategies and treatment goals across several hematologic malignancies.

Meta-Analysis Shows Efficacy, Safety of CAR T-Cell Therapy in R/R Mantle Cell Lymphoma

October 14th 2024

CAR T-cell therapy demonstrated efficacy and manageable safety in mantle cell lymphoma in a systematic review of prospective and real-world studies.

Dr Mehta on Risks of CAR T-cell Therapy in Heavily Pretreated Lymphoma Patients

October 10th 2024

Amitkumar Mehta, MD, discusses CAR T-cell therapy-associated risks in patients with lymphoma who have undergone multiple lines of prior chemotherapy.

NT-I7 After CAR T-Cell Therapy Enhances CAR T Factors in R/R DLBCL

October 7th 2024

NT-I7 with CAR T-cell therapy demonstrated an 81.1% objective response rate in relapsed DLBCL patients and a manageable safety profile.

The OncFive: Top Oncology Articles for the Week of 9/29

October 5th 2024

Perioperative nivolumab receives FDA approval for resectable NSCLC, acalabrutinib sNDA gets priority review for MCL, and more from OncLive this week.

BMS-986393 Shows First-In-Class Potential in Relapsed/Refractory Multiple Myeloma

October 1st 2024

The GPRC5D-targeted CAR T-cell therapy BMS-986393 led to an objective response rate of 96% in patients with relapsed/refractory multiple myeloma.

P-BCMA-ALLO1 May Be Safe, Rapid, and Active Allogeneic CAR T-Cell Therapy in Pretreated R/R Myeloma

September 30th 2024

Treatment with P-BCMA-ALLO1 demonstrated clinical activity and a manageable safety profile in heavily pretreated, relapsed/refractory multiple myeloma.

Anito-Cel Yields 100% Response Rate in R/R Myeloma

September 30th 2024

All patients with relapsed/refractory multiple myeloma experienced a response when treated with anitocabtagene autoleucel in a phase 1 trial.

Using a Molecular Scissors to Improve CAR T-Cell Therapy

September 30th 2024

Mayo Clinic researchers mined the molecular foundations of cancer and uncovered a new reason CAR-T cell therapy fails in some patients.

KarMMa-9 Study of Ide-Cel/Lenalidomide Maintenance in Newly Diagnosed Myeloma Discontinues Enrollment

September 25th 2024

The phase 3 KarMMa-9 trial of ide-cel plus lenalidomide maintenance in newly diagnosed multiple myeloma after ASCT has discontinued enrollment.

Challenges With CAR T-Cell Therapies in T-Cell Lymphomas

September 11th 2024

Jasmine M. Zain, MD, of City of Hope, discuss challenges in CAR-T therapies in patients with T-cell lymphomas.

The OncFive: Top Oncology Articles for the Week of 9/1

September 7th 2024

This list features a snapshot of key August FDA oncology decisions, efforts to integrate health equity into guideline development, and more.

Tisagenlecleucel Climbs into Earlier Lines of Therapy for Pediatric R/R B-ALL

September 4th 2024

Tisagenlecleucel is moving to earlier lines of therapy for pediatric and young adult patients with relapsed/refractory B-cell acute lymphoblastic leukemia.